



PITTFALLS


Ali Akbarzade Pasha MD




67 y o
F/U after Bx ,small
focus of G 3+3 in RT
apical PZ




A



B



C






D





NORMAL CENTRAL ZONE

- posteromedial base-to-midgland PZ
- **ED** in base
- D coronal
- Symmetrical
- Teardrop






Normal CZ: No early enhancement




CZ cancer: Early focal enhancement



Thickening of surgical capsule




A




B




periprostatic venous plexus



A




B




C







(a)



(b)



(c)




(d)


DCE No early focal enhancement



neurovascular bundle




A




B






A




B




C

60 y o
Bx 1 week before MRI
A T1
C $b=1000 \text{ s/mm}^2$



D




E




POST-BIOPSY HEMORRHAGE

- T2 score 5
- ADC/DWI 4
- DCE Early enhancement
- PIRADS 5
- High grade tumor






T1



T2








POAT BIOPSY HEMORRHAGE

- T1 base PZ
- bilateral posteromedial/Rt posterolateral
- T2 score 5
- DCE early enhancement






Post biopsy hemorrhage
Axial T1, Axial T2, DWI and ADC.







A



B



C




D


72 y 0
High PSA
2 previous Bx –
D T2 6 month F/U



FOCAL ACUTE PROSTATITIS


- T2 Lt PZpm apex
- ADC 3
- DCE early focal
- **PIRADS 4**
- Bx FAP





PROSTATITIS







- T2 PZ diffuse
- ADC DWI(1500 mm²/s) score 1
- DCE early diffuse




Post-inflammatory **fibrosis and atrophy**.
Focal atrophy mimics cancer.
See DWI and DCE.



Mimic: Focal Atrophy







67 y o
DRE left rectal nodule
PSA 11 ng/ml



GRANULOMATOUS PROSTATITIS

- **T2** PZpm low signal focus score 3
- 11 mm
- **ADC** score 3
- **DWI** (1500 mm²/s) 3
- **DCE** early enhancement
- **PIRADS 4**









54 y o
PSA 16 ng/ml

T2 9mm focus Rt PZ mid
ADC 3
DWI(b=1500 mm²/s) 3
DCE early enhancement
PIRADS 4
Bx GP






61 y o
DRE Rt pararectal mass




GP

- T2 Rt PZ TZ expansive heterogeneous
- Periprostatic fat
- ADC 5
- DWI $b=1500$ 5
- DCE early enhancement at solid component
rim enhancement at cystic component
- Bx GP







A



B



C






D


69 y o
Hx : High grade non-muscle invasive bladder TCC
and BCG therapy
A&P MRI

T2 Lt PZp apex Hyposignal
ADC 4
DWI b=800 s/mm2 4
DCE(subtraction) nonenhancing
PIRADS 4
Bx Necrotizing GP
Sequela of BCG therapy
9 month F/U stable




Mimic: BPH nodule in PZ







(c)




(d)




(e)



(f)



(a)




(b)

PIRADS ??




ECTOPIC BPH NODULE


- **T2** completely encapsulated score 1
- **ADC/DWI** score 4
- **DCE** Strong early enhancement with wash-out curve
- **PIRADS 1**




(c)



(d)




(e)




(f)






A



B




C

6month F/U


Stromal BPH nodule




Anatomic distortion of high-b-value diffusion-weighted images



A



B



C


Using **AP** phase encoding

using **left-to-right** phase encoding




61 y o

Previous Bx :G3+4 at Lt PZ midgland




A

T2 at Bx proven tumor



B

$b=1000 \text{ s/mm}^2$




C

$b=1500 \text{ s/mm}^2$

Lack of suppression of benign prostate tissue on standard high-b-value diffusion-weighted images




Suboptimal windowing of ADC map




A

T2 PZ bilateral
heterogeneous



B

without any alteration of
window and level from
default settings



C

after selection of optimal
display settings
(window/level settings of
approximately $1600/1600 \times 10^{-6} \text{ mm}^2/\text{s}$)

Bx G 3+4



Checklist

Clinical information

Indication
PSA
Biopsies: date - results

Findings

Prostate volume
PSA density
Postbiopsy hemorrhage

Lesion characteristics

Diameter
Location (39 sector model)
T2 and DWI characteristics
Signs of extraprostatic growth

Conclusion

PI-RADS classification
Morphology and location



PSA density

Prostate volume = Length x Width x Height x 0.52

$$\text{PSA density} = \frac{\text{PSA value}}{\text{Prostate volume}}$$


Prostate volume determines the feasibility of external radiation therapy, which can be performed up to a volume of 55cc.

Please note that this limit is only valid for conventional external radiation.

For proton radiation this limit doesn't exist.

PSA density-values of ≥ 0.20 contribute towards the suspicion of a clinically significant prostate malignancy.





The PSA level in this patient was 5.

The PSA density is $5 : 56.2 = 0,09$.

This is a low PSA density and this patient probably has no clinically significant malignancy.



- The peripheral zone, transition zone, central zone, and anterior fibromuscular stroma have different MRI features
- PI-RADS v2 and mpMRI are widely embraced, but the variability of image quality and performance continues to be a problem
- DWI is the dominant sequence in the peripheral zone, and T2 is the dominant sequence in the peripheral zone (DWI is a close second), assessment for PI-RADS
- Quality efforts are important, including ACR initiatives and quantitative/artificial intelligence tools

